Matt XXXX I'm joined on operator, everyone, our to call. Thanks, Chief fourth quarter Officer. call earnings by Hill, and welcome, and our Financial fiscal year today's
a quick we for in, delve me provide Before call. outline let the
and First, our some revenue during our XXXX let's our as results.
Total quarter of we conclude this some which will before the questions. financial million. performance of the quarter. on backdrop, revenue as guidance, the year-over-year introduced call quarter a made fiscal quarterly then additional we fourth release.
I'll review I'll fourth by we thoughts priorities results in a quarterly for sharing increased discuss for XXXX earnings XX% well and With fourth review to revenue our $XX.X notable in as operational with the our Matt outlook begin progress today's open
revenue growth Advanced products, $XX.X driven increased by was sales Energy to of million. XX% our year-over-year predominantly which total Our
from However, million. XX% year-over-year OEM sales we to strong also products, saw contributions $X.X our of which increased
U.S. our was our was reflecting an of sales Advanced U.S. growth Energy majority year-over-year, XX%, From utilization-based double-digit by a than XX% to by more Energy XX% standpoint, product a from in our by handpieces, customers.
In respectively. of segment. sales fueled in than more was which the And a Advanced handpieces sales primarily growth demand. standpoint, generators growth Energy driven our and driven which more Turning by detailed sales by Advanced discussion geographic uptick drivers of of growth and Advanced our sales sales increased Energy growth to specifically, increased both the the in our
generator U.S. XX% more growth sales, than which increased double-digit year-over-year. saw in also We by
Apyx to sales Our customers. One Console U.S. benefited our generator of from sales the existing system, growth generator next-generation
growth our we the increased the One.
Meanwhile, year-over-year of Advanced equipment States, U.S. at sales sales outside respect handpieces, to their a XX% of existing obtain upgrade will offset system growth XX% by generators new to generator by U.S. our largely generation Apyx on sales to market when sales. them our that our handpieces the sales continued international as year-over-year.
In handpiece trade than discounted sales year-over-year detail in program of United in due further year-over-year. growth growth was global than more and Energy in performance XX% of we decreased Advanced which revenue decreased system beginning discuss reminder, Energy double-digit to generators driven generators XXXX, As introduced impacted, by saw cosmetic for generator pricing summary, launched the to in global This both of new an which slightly and more was sales for to our be prior customers users, we surgery this in capital in demand I shortly.
With enabling the
equipment expectations, which purchases, $XX.X performance we fell the quarter, sales, fourth sales third saw softness prospective cosmetic of market during which the our quarter equipment with million. short overall capital and the in third to shared high Advanced we earnings capital for broader the as interest reminder, Energy As respect in relative that fourth more observed preliminary January, in call.
With revenue guidance the guidance-related last we citing quarter, at earnings our provided We improvements macroeconomic third with were handpiece earnings sequential in we on with our was Energy sales articulated Relative the on quarter. quarter the strong generator our surgery pleased we release assumptions to consistent our call, of customers in Advanced performance to least called our uncertainty a for delaying had rates. the
quickly customers, our to surgeon introducing support moved options prospective further in flexibility. September expand financing to team additional with financial for provide Our them
As we last shared that assumed quarter. call, our environment equipment our guidance on has fourth challenged would in the remain similarly earnings capital the
sales generator capital seasonally growth to However, we QX strongest see equipment year represented our has quarter expected a the as to of sequential traditionally sales generator in perspective.
The from quarter fourth the QX from macroeconomic as continued the broader anticipated proved fourth we environment. more be to related as delaying challenging quarter in had concerns financing given well the more than environment customers investments uncertainty to with prospective
generated growth fueled the Advanced by generate of headwinds. the our quarter to result, third.
Ultimately, in significant global we a flat Energy revenue was to year-over-year, by generator managed spite growth these in increasing year-over-year business internationally. XX% more essentially fourth U.S. in With in and sales the than As relative growth
our of respectively, to full-year enabled with significant a on in in to reduction focus double-digit to to along deliver and continued stockholders quarter our controlling revenue loss us our and cash in XX% improvements Our revenue this in performance expenses, the attributable addition in year. sales return fourth basis performance, our on adjusted XX%, annual to positioned XXXX.
And in past used growth net us EBITDA operations loss
our initial awareness full market Handpiece, Micro our From balance during We surgeon key the to team. areas Turning completed Handpiece fourth products, the introducing we initiated made late launch launching of our market, limited the operational and the protocols.
In which Micro year-end. during progress by of we of a sheet November, to raising new commercial product stated notable new important goal of feedback our highlights. with our enhancing the U.S. standpoint, strengthening the in in weeks with release our several quarter, consistent fourth quarter training quarter, Renuvion provided enhance us our
during the limited following weeks have the consistent launch, obtained our U.S. initial release. pleased been been see feedback that our response the we has to During the from market customers with
for shaft Renuvion half is body. it diameter that in contracting profile of accessing As smaller the areas delicate delivering a energy ideal soft Micro a our device's with reminder, shared and that and the width have APR our Handpiece.
Surgeons of more a tissue profile Handpiece Renuvion sensitive instrument smaller features the make the
completing capabilities only One remember Handpiece expanding of existing with our our to latest Console. compatible Apyx offering, Renuvion the addition Micro generator In the and that our is product generation system,
the -- addition to represents to Handpiece adopting system. Apyx the important next-generation In our One's Renuvion benefit Micro features, enhanced next-generator another generator
medical indications team addition profile strong latest during of In highlight as on shows Surgery well use. our remained which the FDA clinical educating technology and Renuvion specific in meetings in the October. late quarter. clearances the market was The trade fourth Micro for with our efficacy We the safety as and introducing ASPS focused of Plastic about the to Handpiece, X hosted participated meeting our
at featured clinicians. event XX programming approximately session Our educational led an by the from attendance surgeons, X drew which
hosted awareness quarter during the XX the attended users featured a year This in Renuvion new the surgeon other XXX from fourth during America the initiatives, end procedures, by role in more real including the the Renuvion community. the clinicians to the develop the of panel level, and emphasizes speakers, of events most near XX broaden at and body our materials we also results course campaign the medical patient quarter, second presentations launching obtained medical Latin podium from and event our successful meeting discussions that We to industry was in its approximately technology with of XX presentations And helping our fourth was than meetings customers. at our illustrating some of Renuvion's technology contouring continue capabilities DTC by with countries.
Ultimately, patients.
our efforts in with and enhance made executive We of to sales, marketing personnel. progress also the leadership addition important teams our key
team fourth and quarter. last As our we the shared reorganization quarter, of during a we strategic conducted sales marketing
top side, overall Asia. several From marketing direct planned our team.
Internationally, of performers expanded to distributor of in in team our some also sales manage East a leadership territory in the implemented of the U.S. On to we the improve relations brought perspective, sales new within the our departures hired productivity reps for we and sales Senior we of joins managing team over experience the including other device the significant device and recently, experience of industry, in surgery direct-to-consumer experience head advertising a who developing campaigns a Director companies of a extensive our in care cosmetic marketing most new with added medical we and of with space. decade new and Marketing, medical in health our
and More were our talent, to than to over operational financial the of of years devoted of Hill we Matt this and as leadership the executive our pleased experience. joined where the key Apyx today's I'd CFO to served life new has companies, years Biotech addition have his Medical of like been on XX announce members with the and traded Matt Matt In recently appointment take Financial PDS Officer. XX team career Chief industry, welcome most publicly call to Matt X of team. opportunity science Strata Sciences. Skin at to the other as
which balance of financial of XXXX prior we've enhanced fees proceeds under secured new well course leverage and transaction X-year to expanded our pleased used at million over We of an progress the all We as Lastly, million other to expenses transactions. this sheet organization made $XX.X in and the new providing as of our proceeds entered the related facility, million to into $XX senior, agreement Perceptive were to $X.X the loans, summary, XXXX transitional up whole closing. objectives. access facility out as X for capital important at an satisfy Advisors $XX us with these strategic for we approximately stated to approximately of to terms.
In as proved with a Medical. a year more credit with obligations favorable agreement a be Apyx flexibility. We set condition and million to negotiate We
remaining our FDA for additional ability First, use improving indications the to clinical safety to limitations of communication our market and the addressing technology. secure
enhance new to our Second, portfolio. product
Third, evidence profitability. expenses pleased towards to objectives these of during that course to supporting able progress use portfolio accomplish the the And team clinical each of products. our of while our X the manage fourth, to was of year. I'm driving our expand our
well presence believe fourth With initiatives expand in release. more and in now review detail, the we with equivalents global fund million of sustainable cash the to we with are positioned in sufficiently achieving capitalized financial and Matt? all surgery we results to fronts, our as XXXX, progress that today's these year-end, introduced believe our continue to target are growth $XX in of and we market financial for along we we at cosmetic on quarter future.
Matt the guidance our the which made profitable will
